Analysis shows AI and machine learning boost production levels in PPE supply chains, indicating enhanced operational resilience.
This article examines the crucial role that artificial intelligence and machine learning play in strengthening healthcare manufacturing supply chains, with a particular focus on personal protective equipment. The COVID-19 pandemic laid bare major weaknesses in global healthcare supply networks, specifically the production and supply of N95 respirators. The combination of AI/ML with Manufacturing Execution Systems and Industrial Internet of Things technologies revolutionized the capacity of the industry to scale production at high speed while keeping quality intact. The top manufacturers utilized these digital capabilities to exponentially expand production capacity, maximize utilization of materials, and deliver consistent quality in spite of record-breaking demand. Machine learning algorithms were key to working with enormous production data sets to improve equipment performance, forecast maintenance requirements, lower error rates, and conserve material waste. The technological platform supporting such advancements includes inclusive sensor networks, effective data integration layers, advanced analytics engines, digital twin simulations, and automated control systems. Case examples of large manufacturers illustrate variable implementation practices and results. The rapid digital transformation experienced through this crisis phase represents real change in manufacturing, introducing new standards for operational resilience and agility. In addition to reducing the demands of short-term epidemics, these technologies also provide routes for future progressive improvements in healthcare building architecture, representing the strategic value of investments running in AI/ML in important supply chains. While the implementation allows for significant benefits in the amount of production, velocity, quality, and visibility within the supply chain, comprehensive manufacturing price remains a significant obstacle in increasing these capabilities in the network, especially for small producers who face obstacles to resources and technology.
No takes yet. Share an insight, caveat, or question.
Natarajan Ravikumar (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: